12.2 Lesions with Upgrade Potential

What "Upgrade Potential" Means on This Exam

Upgrade potential is a pathology concept, not a BI-RADS category you assign at the console. A core-needle biopsy samples part of a lesion. If that sample shows atypia or another high-risk histology, the rest of the lesion — still in the breast — may contain ductal carcinoma in situ (DCIS) or invasive carcinoma that the needle missed, or the atypia may be reclassified as carcinoma when the entire specimen is reviewed. That jump from "atypia on core" to "cancer on excision" is the upgrade.

The mammography technologist does not diagnose ADH or LCIS from a mammogram. You recognize the target that led to biopsy (grouped calcifications, distortion, a mass), you perform or assist with the localizing procedure, and you understand why the report may say "excision recommended" even though the word "cancer" is not in the core diagnosis. Concordance still belongs to the radiologist: a highly suspicious mammographic mass with only benign core histology is a different problem (possible sampling miss) from a cluster of calcifications that yielded ADH.

Do not memorize invented upgrade percentages. Published rates vary by lesion type, biopsy device, and how much atypia is present. The exam-stable fact is the direction of risk: these diagnoses can hide or upgrade to in situ or invasive disease, so they are not treated like a simple cyst.

The Atypia and Lobular Neoplasia Group

Atypical ductal hyperplasia (ADH)

ADH is a clonal ductal proliferation that looks like low-grade DCIS but does not meet full histologic criteria for DCIS (extent and completeness of involvement). It is frequently discovered because screening calcifications were biopsied — amorphous or coarse heterogeneous calcifications are common targets, not a unique ADH signature. Mammography does not display a label that says ADH. After a core diagnosis of ADH, surgical excision is often recommended because residual DCIS or invasion may be found in the remainder of the calcifications. Your practical role is precise calcification sampling (the specimen radiograph should show the target calcifications) so the pathologist is grading the lesion that was actually seen on the mammogram.

Atypical lobular hyperplasia (ALH) and LCIS

ALH and lobular carcinoma in situ (LCIS) are lobular neoplasia. Cells fill lobular units; they typically lack E-cadherin (a stain the pathologist uses; you will not see it on the image). Classic LCIS is usually an incidental finding in tissue removed for another reason. It is not a mammographic mass with a classic outline the way a fibroadenoma is. It is a marker of increased future risk in both breasts, not a small DCIS-like target you can "see and remove" as the entire disease. Pleomorphic LCIS is managed more like DCIS (excision) because its biology is more aggressive; that distinction is histologic.

ALH is the lesser quantitative end of the same lobular spectrum. Like LCIS, it is usually incidental. When ALH or classic LCIS is the only finding on a core done for calcifications, management still depends on concordance and associated lesions — another reason the technologist should not translate "LCIS" into "ignore" or into "cancer" on the exam.

American Cancer Society patient-facing pathology explainers treat LCIS as in situ disease that is not invasive cancer and contrast it with invasive carcinoma that has grown beyond the lining layer. That is the language to keep straight: in situ means the cells have not invaded supporting tissue; upgrade means excision might still find invasion or DCIS nearby.

Papilloma with atypia

A papilloma without atypia and a papilloma with atypia are not the same risk object. Atypia inside a papilloma (or an atypical papillary lesion) raises concern that DCIS or invasion is in the unsampled duct system. Imaging may show a retroareolar mass, a dilated duct, or almost nothing except discharge. The upgrade conversation starts after histology, not from the mammogram alone. If the blueprint lists papilloma with atypia separately from ordinary papilloma, the reason is this higher chance that excision will reveal carcinoma.

Flat epithelial atypia (FEA)

Flat epithelial atypia is a columnar cell lesion with low-grade cytologic atypia lining dilated acini, often with secretions and calcifications. Like ADH, it is a microscope diagnosis after a stereo or tomosynthesis-guided biopsy of calcs. Management has been debated in the surgery literature; for the ARRT exam, file FEA with the other atypical, excision-discussed diagnoses rather than with simple fibrocystic change. It can coexist with ADH, DCIS, or invasion in the same region — that coexistence is the upgrade problem.

Architectural Distortion: Radial Scar versus Surgical Scar

Radial scar (complex sclerosing lesion)

A radial scar (when larger, complex sclerosing lesion) is a benign fibroelastotic core with ducts pulled inward, producing architectural distortion. The classic mammographic description is a "black star": long, thin spicules radiating from a lucent or radiolucent center, without a dense central mass. Digital breast tomosynthesis detects this pattern more often than 2D alone. The problem is simple: spiculated distortion is also how many cancers look. Imaging cannot reliably separate radial scar from invasive carcinoma or from a mix of radial scar plus ADH/DCIS. These lesions are typically biopsied. If the core shows radial scar — especially with atypia — excision is often advised because of upgrade potential.

Distortion that is a surgical scar

A postsurgical scar can also be spiculated distortion, skin retraction, and a band of density. Distinguishing features live in the history and markers:

• Known date and site of lumpectomy, reduction, or biopsy, with a scar marker on the skin incision
• Distortion that points to the skin scar and is stable or contracts on successive years
• Surgical clips or a seroma cavity in the same place

A radial scar has no surgical explanation. New distortion years after surgery, distortion remote from the scar, or distortion with suspicious calcifications is not "just the old scar." The technologist's job is to mark the scar consistently, include it on both CC and MLO (and tomosynthesis slices), and not crop the posterior tissue where a new distortion might hide.

Cancer, radial scar, and surgical scar can look alike on a single still image. The exam will give you the clue (recent surgery vs no surgery; lucent center vs dense mass; stability vs new).

Phyllodes Tumor

A phyllodes tumor arises from breast stroma (the supporting connective tissue), not from duct lining in the way DCIS does. Histology grades it benign, borderline, or malignant. All three can present as a circumscribed, oval or lobulated mass that looks like a fibroadenoma on mammography and ultrasound. The clinical flag is rapid growth — a mass that enlarges over weeks to a few months, sometimes becoming large enough to stretch the skin. Malignant phyllodes can metastasize hematogenously (lung, bone), more like a sarcoma than like typical ductal carcinoma nodal spread.

Because imaging overlap with fibroadenoma is real, growth is the reason a "probably fibroadenoma" gets biopsied. Treatment of phyllodes is surgical excision with a margin, not observation, even when the histology is benign, because of local recurrence risk. The mammographer documents size change, obtains a full field of view so a large mass is not clipped, and does not reassure the patient that a rapidly enlarging "smooth" mass is harmless.

American Cancer Society materials note that a less common breast tumor called phyllodes can start in the stroma. That origin (stroma, not duct epithelium) is the fact that separates it from IDC/DCIS on a knowledge question.

Technologist Workflow After a High-Risk Core Result

1. The finding that was biopsied should still be visible and marked on subsequent diagnostic images (clip, residual calcifications, residual distortion).
2. A clip that has migrated away from the calcifications is a quality issue — report it; upgrade risk is meaningless if the wrong tissue was sampled.
3. Wire, seed, or radar localization for excision is a procedures skill: the specimen radiograph should show the target, the clip, and (for calcs) the calcifications.
4. You still do not tell the patient "it is cancer" or "it is nothing" from an ADH or radial-scar report. High-risk histology is a conversation between pathology, radiology, and surgery.

Exam trap: LCIS on a core is not the same as DCIS. DCIS is treated as a local malignant process in the ducts (Section 12.3). Classic LCIS is a bilateral risk marker that was often found by accident. Pleomorphic LCIS is the exception that is handled more like DCIS. If a question stems "incidental lobular neoplasia," think risk marker, not a spiculated mass you should have seen on the mammogram.